Research & Studies
Share your love
Adopting Emerging Therapies in Dry Eye Care | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
AI in ophthalmology research: Ethical implications for medical students | Ophthalmology Times
Training students to use AI responsibly ensures effective, ethical integration into research and medical education. (Image credit: AdobeStock/ABDULELLAH) Over the past decade, earning an ophthalmology residency spot has become more difficult and competitive.1 Between 2021 and 2024, the overall match…
The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Dante Pieramici, MD, FASRS; Dean Eliott, MD; and Charles C. Wykoff, MD, PhD, FASRS; provide an overview of macular…
Customized Clarity: Navigating IOL Options for Optimal Patient Care | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Tanner Ferguson, MD, and Taj Nasser, MD, FWCRS, discuss the management of astigmatism at the time of cataract surgery,…
Key Clinical Takeaways From Case-Based Discussions on Advanced IOL Selection | Ophthalmology Times
This concluding segment synthesizes the most important lessons attendees gained from reviewing three diverse cataract cases. For case one, the primary takeaway was the importance of anchoring IOL selection to patient identity, lifestyle, and expectations, with the enVista Envy lens…
IOL Selection and Expectation Management in a Hyperopic Patient With Astigmatism Considering Advanced Lenses | Ophthalmology Times
This final case discussed a 58-year-old hyperopic male with significant astigmatism and visually limiting cataracts who initially presented seeking LASIK but was determined to be a poor refractive surgery candidate. The panel reviewed corneal topography demonstrating oblique astigmatism and low…
Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases | Ophthalmology Times
This segment examines real-world comparisons between faricimab and aflibercept 8 mg in terms of retinal drying, durability, and intraocular pressure (IOP) management. Clinicians note that both agents extend treatment intervals modestly—often by about one additional week compared with standard 2…
Advanced IOL Selection in a Low Night-Driving Patient With Bilateral Cataracts | Ophthalmology Times
This segment reviews a case-based roundtable discussion focused on advanced intraocular lens (IOL) selection in cataract surgery, highlighting the importance of patient-centered decision-making. The case involved a 69-year-old retired pastor engaged in foreign mission work who presented with bilateral cataracts,…
How AI is reshaping ophthalmology in 2025 and beyond | Ophthalmology Times
(Image Credit: AdobeStock/ImageFlow) Artificial intelligence (AI) continues to evolve with improved diagnostic abilities, individualized patient treatments, and enhanced surgical accuracy. Some key developments include the analysis of retinal scans that provide earlier disease detection and the ability to spot tumors…
8 things to know about aflibercept 8 mg for retinal vascular disease | Ophthalmology Times
The US Food and Drug Administration (FDA) approved aflibercept 8 mg (EYLEA HD) for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to 8-week dosing after an initial dosing period last month. The latest…